CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
53.07
-1.09 (-2.01%)
At close: Aug 20, 2025, 4:00 PM
53.66
+0.59 (1.11%)
After-hours: Aug 20, 2025, 7:59 PM EDT
CRISPR Therapeutics AG Revenue
CRISPR Therapeutics AG had revenue of $892.00K in the quarter ending June 30, 2025, with 72.53% growth. This brings the company's revenue in the last twelve months to $38.05M, down -81.18% year-over-year. In the year 2024, CRISPR Therapeutics AG had annual revenue of $37.31M, down -89.95%.
Revenue (ttm)
$38.05M
Revenue Growth
-81.18%
P/S Ratio
119.86
Revenue / Employee
$96,819
Employees
393
Market Cap
4.83B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.31M | -333.89M | -89.95% |
Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CRSP News
- 6 days ago - Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade - Benzinga
- 6 days ago - Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025 - Seeking Alpha
- 16 days ago - CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big - Seeking Alpha
- 5 weeks ago - Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade) - Seeking Alpha
- 7 weeks ago - CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline - GlobeNewsWire
- 2 months ago - Crispr Therapeutics: Betting On A One-Shot Future - Seeking Alpha
- 2 months ago - CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) - Seeking Alpha